covid 19 vaccine
COVID-19 trials proliferated rapidly during the pandemic and now encompass antiviral treatments, long COVID management, and ongoing vaccine refinements for new variants. The platform trial model — where multiple interventions share a single control arm — was pioneered at scale for COVID-19 (RECOVERY, ACTIV-3, SOLIDARITY) and has since been adopted across other disease areas.
Active trials address long COVID (fatigue, cognitive impairment, autonomic dysfunction), antiviral combinations for high-risk outpatients, mucosal vaccines for variant-resistant immunity, and mechanistic studies into post-COVID organ damage. Paxlovid rebound, nirmatrelvir resistance, and immunocompromised host management are current investigation areas.